Microbiome medicine sharpens its focus in small animal care
Bottom line
Microbiome medicine in small animal practice is moving from promise to a more evidence-based middle ground. A new review in Veterinary Clinics of North America: Small Animal Practice argues that dietary modulation, often paired with fiber, should remain the first-line strategy for dogs and cats with enteropathy, while fecal microbiota transplantation, or FMT, may have a role in selected cases of marked dysbiosis or specific acute disease settings. That framing lines up with newly published canine data: a randomized controlled trial in dogs with chronic enteropathy found no significant added clinical benefit from a single retention-enema FMT plus diet change compared with diet change alone by day 90, while a separate placebo-controlled trial in canine parvovirus reported faster clinical recovery with a regimen that combined a single enema with 14 days of oral lyophilized FMT capsules. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the takeaway is practical: microbiome modulation isn't one thing, and the evidence now points to different tools for different cases. In chronic enteropathy, diet-first management still has the strongest support, and a one-time enema FMT shouldn't be expected to reliably improve outcomes on top of diet alone based on current randomized data. In contrast, parvovirus may be a more promising use case for adjunctive FMT, especially if lower-cost, spectrum-of-care protocols can shorten hospitalization and reduce treatment intensity. Companion animal FMT guidelines published in 2024 also reflect that the field is maturing, with more attention to donor screening, product preparation, and patient selection rather than broad enthusiasm alone. (pubmed.ncbi.nlm.nih.gov)
What to watch: Expect the next phase of this field to focus less on whether FMT works in general, and more on which patients, dosing schedules, donor protocols, and delivery methods actually change outcomes. (sciencedirect.com)
Microbiome modulation is becoming more clinically defined in veterinary medicine, and the newest signal from the literature is a narrowing one: start with diet, use FMT more selectively, and match the intervention to the disease. A new review by Jan Suchodolski and Linda Toresson places dietary modulation, potentially combined with fiber, at the center of microbiome-directed care for acute and chronic enteropathy, while positioning FMT as a tool for a subset of patients with substantial dysbiosis or difficult-to-manage disease. (eurekamag.com)
That more measured view arrives as controlled clinical data on FMT in dogs become easier to compare. In chronic enteropathy, a randomized controlled trial published in the Journal of Small Animal Practice evaluated adjunctive FMT delivered as a single retention enema and found no clear clinical advantage over diet change alone. Both groups improved at similar rates by day 90, and the authors noted that the small sample size means a type II error can't be excluded. (pubmed.ncbi.nlm.nih.gov)
The picture looks different in canine parvovirus. In a prospective, double-blinded, placebo-controlled trial involving 27 client-owned dogs infected naturally with CPV, investigators tested a more intensive “spectrum-of-care” regimen: one FMT enema at admission followed by 14 days of oral lyophilized capsules. According to the study summary, dogs in the FMT group had shorter hospitalization and needed fewer medications, while the placebo arm was stopped early after interim analysis because of excess withdrawals tied to worsening clinical status. The treatment did not reduce viral shedding or trigger a measurable host immune response, suggesting the benefit may have come through improved gut recovery or supportive stabilization rather than direct antiviral effects. (eurekamag.com)
That distinction matters because it reinforces a broader point from the review literature: dysbiosis is not a diagnosis by itself, and microbiome-directed therapies are unlikely to perform the same way across chronic inflammatory disease, acute infectious enteritis, obesity, and other emerging indications. Prior observational work in dogs with chronic enteropathy has suggested some dogs improve with repeated or adjunctive FMT, and newer studies continue to explore repeated dosing and metabolomic effects. But the controlled chronic-enteropathy trial adds an important note of restraint, especially for clinicians considering one-off enema FMT as an add-on to standard diet trials. (pmc.ncbi.nlm.nih.gov)
Industry and academic infrastructure around FMT is also catching up. Ohio State researchers have described building a Companion Animal Fecal Bank and advancing studies in parvovirus and obesity, while Winston, who chairs the Companion Animal Fecal Microbiota Transplant Consortium, said in 2024 that general-practice guidelines were intended to help clinicians screen donors, prepare products, and identify appropriate candidates. Those guidelines were subsequently published in Advances in Small Animal Care in 2024, signaling that FMT is shifting from improvised case-by-case use toward a more standardized clinical framework. (vmc.vet.osu.edu)
Why it matters: For veterinary teams, this is a useful correction to the early FMT narrative. The most defensible message for pet parents today is that microbiome modulation starts with fundamentals: diet, fiber, diagnosis of the underlying enteropathy, and careful reassessment. FMT may still be reasonable in selected cases, particularly acute infectious disease such as parvovirus or refractory chronic enteropathy, but protocol details appear to matter. A single rectal infusion may not be enough in chronic disease, while multi-dose regimens could prove more clinically meaningful. That has implications for case selection, informed consent, workflow, biosafety, and expectations around cost and benefit. (pubmed.ncbi.nlm.nih.gov)
There are also operational issues clinicians can't ignore. The companion-animal guidelines emphasize donor screening and standardized preparation, and related work has raised questions about viability losses after freezing and the need for more consistent reporting of FMT methods. In other words, the field is no longer just asking whether stool transfer can help; it's asking what constitutes a quality-controlled biologic product in practice. (sciencedirect.com)
What to watch: The next developments are likely to come from larger controlled trials, repeated-dose protocols, and better phenotype matching, especially in chronic enteropathy, where clinicians now have growing reason to suspect that response depends on disease subtype, dysbiosis severity, and how FMT is delivered. (nature.com)